Quick Takeaways
- Deep Track Capital, LP filed SCHEDULE 13G for Ocular Therapeutix, Inc Common Stock, $0.0001 par value per share (OCUL).
- Disclosed ownership: 5.1%.
- Date of event: 05 Feb 2026.
Deep Track Capital, LP - 05 Feb 2026 SCHEDULE 13G Report for Ocular Therapeutix, Inc Common Stock, $0.0001 par value per share (OCUL)
- Filing Manager
- Deep Track Capital, LP
- Reporting Manager
- Deep Track Capital, LP
- Symbol
- OCUL
- Shares outstanding
- 218,988,928 shares
- Disclosed Ownership
- 11,234,132 shares
- Ownership
- 5.1%
- Form type
- SCHEDULE 13G
- Filing time
- 10 Feb 2026, 16:38:25 UTC
- Date of event
- 05 Feb 2026
- Previous filing
- 10 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Deep Track Capital, LP disclosed 5.1% ownership in Ocular Therapeutix, Inc Common Stock, $0.0001 par value per share (OCUL) on 05 Feb 2026."
What Changed
- Previous schedule filing date: 10 Feb 2026.
- Current filing was accepted on 10 Feb 2026, 16:38.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Deep Track Capital, LP | 5.1% | 11,234,132 | 0 | 0 | /s/ David Kroin | David Kroin, Managing Member of the General Partner of the Investment Adviser | |
| Deep Track Biotechnology Master Fund, Ltd. | 5.1% | 11,234,132 | 0 | 11,234,132 | /s/ David Kroin | David Kroin, Director | |
| David Kroin | 5.1% | 11,234,132 | 0 | 11,234,132 | /s/ David Kroin | David Kroin |